Epstein-Barr virus infection in patients with MOGAD.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2025-01-01 Epub Date: 2024-12-13 DOI:10.1177/13524585241298065

Giorgia T Maniscalco, Alessandro Dinoto, Maria C Foglia, Maria E Di Battista, Ornella Moreggia, Daniele Di Giulio Cesare, Michela Williams, Francesca W Rossi, Sara Carta, Vanessa Chiodega, Sergio Ferrari, Assunta Viola, Amato de Paulis, Vincenzo Andreone, Sara Mariotto

{"title":"Epstein-Barr virus infection in patients with MOGAD.","authors":"Giorgia T Maniscalco, Alessandro Dinoto, Maria C Foglia, Maria E Di Battista, Ornella Moreggia, Daniele Di Giulio Cesare, Michela Williams, Francesca W Rossi, Sara Carta, Vanessa Chiodega, Sergio Ferrari, Assunta Viola, Amato de Paulis, Vincenzo Andreone, Sara Mariotto","doi":"10.1177/13524585241298065","DOIUrl":null,"url":null,"abstract":"Background: Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking.Objective: To compare EBV serological status in MOGAD versus MS.Methods: We measured antibodies to Epstein-Barr nuclear antigen (EBNA-1) and viral capsid antigen (VCA) antigens in 129 patients (MS = 74, MOGAD = 55) by chemiluminescence immunoassays.Results: VCA-IgG were detected in 97.3% of MS and 96.4% of MOGAD cases, while EBNA-1-IgG in 97.3% of MS and 80% of MOGAD (p = 0.001). EBNA-1 (p < 0.001) and VCA (p = 0.03) antibodies levels were higher in MS patients.Conclusion: EBV antibodies are higher in MS versus MOGAD, suggesting a possible different role of EBV in the pathogenesis of the two conditions.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"117-120"},"PeriodicalIF":4.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241298065","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking.

Objective: To compare EBV serological status in MOGAD versus MS.

Methods: We measured antibodies to Epstein-Barr nuclear antigen (EBNA-1) and viral capsid antigen (VCA) antigens in 129 patients (MS = 74, MOGAD = 55) by chemiluminescence immunoassays.

Results: VCA-IgG were detected in 97.3% of MS and 96.4% of MOGAD cases, while EBNA-1-IgG in 97.3% of MS and 80% of MOGAD (p = 0.001). EBNA-1 (p < 0.001) and VCA (p = 0.03) antibodies levels were higher in MS patients.

Conclusion: EBV antibodies are higher in MS versus MOGAD, suggesting a possible different role of EBV in the pathogenesis of the two conditions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MOGAD 患者的 Epstein-Barr 病毒感染。

背景：爱泼斯坦-巴氏病毒（EBV）感染会增加患多发性硬化症（MS）的风险。目前还缺乏关于成人髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）的数据：比较多发性硬化症与 MS 的 EBV 血清学状态：我们用化学发光免疫测定法测定了129名患者（MS=74人，MOGAD=55人）的EB病毒核抗原（EBNA-1）和病毒壳抗原（VCA）抗体：97.3%的MS和96.4%的MOGAD病例检测到VCA-IgG，97.3%的MS和80%的MOGAD病例检测到EBNA-1-IgG（p = 0.001）。EBNA-1（p < 0.001）和VCA（p = 0.03）抗体水平在多发性硬化症患者中更高：结论：多发性硬化症患者的 EBV 抗体水平高于 MOGAD 患者，这表明 EBV 在这两种疾病的发病机制中可能扮演着不同的角色。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585